Wealth Enhancement Advisory Services LLC bought a new position in Humana Inc. (NYSE:HUM) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 3,227 shares of the insurance provider’s stock, valued at approximately $772,000.
A number of other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in Humana by 2,281.7% in the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after buying an additional 11,867,056 shares during the period. FMR LLC increased its stake in shares of Humana by 57.9% in the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock worth $1,041,184,000 after buying an additional 1,851,197 shares during the period. Renaissance Technologies LLC increased its stake in shares of Humana by 84.3% in the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock worth $554,867,000 after buying an additional 1,231,400 shares during the period. Wellington Management Group LLP increased its stake in shares of Humana by 2,651.1% in the first quarter. Wellington Management Group LLP now owns 775,755 shares of the insurance provider’s stock worth $159,915,000 after buying an additional 747,557 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of Humana by 413.8% in the first quarter. AQR Capital Management LLC now owns 736,019 shares of the insurance provider’s stock worth $151,723,000 after buying an additional 592,772 shares during the period. Hedge funds and other institutional investors own 99.13% of the company’s stock.
Humana Inc. (HUM) opened at 247.28 on Friday. The firm’s 50-day moving average is $241.05 and its 200 day moving average is $224.57. The firm has a market capitalization of $35.74 billion, a P/E ratio of 20.34 and a beta of 0.91. Humana Inc. has a 52-week low of $163.50 and a 52-week high of $255.27.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. During the same period in the previous year, the business earned $2.30 EPS. Equities analysts anticipate that Humana Inc. will post $11.55 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Tuesday, August 29th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.60 annualized dividend and a yield of 0.65%. Humana’s payout ratio is currently 13.06%.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2017/08/19/3227-shares-in-humana-inc-hum-acquired-by-wealth-enhancement-advisory-services-llc-updated-updated.html.
HUM has been the subject of a number of recent research reports. UBS AG reiterated a “neutral” rating and set a $250.00 price objective (up previously from $237.00) on shares of Humana in a research report on Wednesday, August 9th. Zacks Investment Research downgraded Humana from a “buy” rating to a “hold” rating in a research report on Monday, April 24th. Cowen and Company reiterated a “buy” rating and set a $230.00 price objective on shares of Humana in a research report on Friday, July 14th. BidaskClub upgraded Humana from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $223.00 price objective (up previously from $200.00) on shares of Humana in a research report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $244.35.
In other Humana news, VP Heidi S. Margulis sold 1,500 shares of Humana stock in a transaction on Friday, May 26th. The shares were sold at an average price of $231.96, for a total value of $347,940.00. Following the sale, the vice president now directly owns 8,150 shares in the company, valued at approximately $1,890,474. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Brian P. Leclaire sold 4,971 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the transaction, the senior vice president now owns 14,258 shares in the company, valued at $3,421,920. The disclosure for this sale can be found here. Insiders sold a total of 41,406 shares of company stock worth $10,355,086 over the last quarter. Company insiders own 0.80% of the company’s stock.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
What are top analysts saying about Humana Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Humana Inc. and related companies.